VYNE Therapeutics Inc. – NASDAQ:VYNE
VYNE Therapeutics stock price today
VYNE Therapeutics stock price monthly change
VYNE Therapeutics stock price quarterly change
VYNE Therapeutics stock price yearly change
VYNE Therapeutics key metrics
Market Cap | 39.38M |
Enterprise value | N/A |
P/E | -0.28 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 3.18 |
Price/Book | 0.21 |
PEG ratio | N/A |
EPS | -5.43 |
Revenue | 423K |
EBITDA | -30.76M |
Income | -29.07M |
Revenue Q/Q | -1.01% |
Revenue Y/Y | 6.28% |
Profit margin | -898.84% |
Oper. margin | -514.48% |
Gross margin | 60.88% |
EBIT margin | -514.48% |
EBITDA margin | -7272.81% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVYNE Therapeutics stock price history
VYNE Therapeutics stock forecast
VYNE Therapeutics financial statements
| Jun 2023 | 135K | -10.05M | -7450.37% |
|---|---|---|---|
| Sep 2023 | 114K | -6.58M | -5775.44% |
| Dec 2023 | 76K | -6.18M | -8142.11% |
| Mar 2024 | 98K | -6.24M | -6368.37% |
| 2025 | 250K | -40.7M | -16280% |
|---|---|---|---|
| 2026 | 250K | -46.2M | -18480% |
| 2027 | 10.25M | -7.70M | -75.17% |
| 2028 | 13.6M | -11.81M | -86.87% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 24959000 | 7.68M | 30.8% |
|---|---|---|---|
| Sep 2023 | 19267000 | 7.76M | 40.29% |
| Dec 2023 | 97685000 | 8.95M | 9.16% |
| Mar 2024 | 91676000 | 8.30M | 9.06% |
| Jun 2023 | -9.57M | 0 | -5K |
|---|---|---|---|
| Sep 2023 | -5.15M | 0 | -47K |
| Dec 2023 | -5.13M | -62.35M | 82.66M |
| Mar 2024 | -7.98M | -3.56M | -4K |
VYNE Therapeutics alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 10 |
| Apr 2024 | 10 |
| May 2024 | 10 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
VYNE Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 30000 | 0 |
| Nov 2023 | 13000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LEPORE PATRICK G director | Common Stock | 13,000 | $3.91 | $50,778 | ||
Purchase | HARSCH MUTYA officer: Chief Le.. | Common Stock | 10,000 | $2.5 | $25,000 | ||
Purchase | LEPORE PATRICK G director | Common Stock | 20,000 | $2.48 | $49,680 | ||
Purchase | LEPORE PATRICK G director | Common Stock | 12,500 | $1.02 | $12,700 | ||
Purchase | LEPORE PATRICK G director | Common Stock | 12,500 | $1.6 | $20,000 | ||
Sale | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 250,000 | $1.74 | $435,000 | ||
Sale | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 250,000 | $1.84 | $460,000 | ||
Sale | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 338,897 | $2.23 | $755,740 | ||
Purchase | LEPORE PATRICK G director | Common Stock | 12,500 | $3.6 | $44,963 | ||
Sale | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 1,000,000 | $3.67 | $3,670,000 |
| Quarter | Transcript |
|---|---|
| Q3 2021 10 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 12 Aug 2021 | Q2 2021 Earnings Call Transcript |
-
What's the price of VYNE Therapeutics stock today?
One share of VYNE Therapeutics stock can currently be purchased for approximately $0.34.
-
When is VYNE Therapeutics's next earnings date?
Unfortunately, VYNE Therapeutics's (VYNE) next earnings date is currently unknown.
-
Does VYNE Therapeutics pay dividends?
No, VYNE Therapeutics does not pay dividends.
-
How much money does VYNE Therapeutics make?
VYNE Therapeutics has a market capitalization of 39.38M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.11% to 424K US dollars.
-
What is VYNE Therapeutics's stock symbol?
VYNE Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "VYNE".
-
What is VYNE Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of VYNE Therapeutics?
Shares of VYNE Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are VYNE Therapeutics's key executives?
VYNE Therapeutics's management team includes the following people:
- Mr. David T. Domzalski Chief Executive Officer, Pres & Director(age: 58, pay: $907,720)
- Ms. Mutya Harsch J.D. Gen. Counsel, Chief Legal Officer & Company Sec.(age: 50, pay: $523,260)
-
How many employees does VYNE Therapeutics have?
As Jul 2024, VYNE Therapeutics employs 10 workers.
-
When VYNE Therapeutics went public?
VYNE Therapeutics Inc. is publicly traded company for more then 7 years since IPO on 25 Jan 2018.
-
What is VYNE Therapeutics's official website?
The official website for VYNE Therapeutics is vynetherapeutics.com.
-
Where are VYNE Therapeutics's headquarters?
VYNE Therapeutics is headquartered at 520 U.S. Highway 22, Bridgewater, NJ.
-
How can i contact VYNE Therapeutics?
VYNE Therapeutics's mailing address is 520 U.S. Highway 22, Bridgewater, NJ and company can be reached via phone at +800 7757936.
VYNE Therapeutics company profile:
VYNE Therapeutics Inc.
vynetherapeutics.comNASDAQ
10
Biotechnology
Healthcare
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Bridgewater, NJ 08807
CIK: 0001566044
ISIN: US92941V3087
CUSIP: 92941V209
